Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

4 Customer Reviews

  • Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

    BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

  • Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

    Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

    The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

    Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{\5SGlvcGmkaYTpc44hd2ZiaIXtZY4hVk:VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhOy54NnWtNFUh|ryP MXPTRW5ITVJ?
CAL-51 cell NEPnN2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmLiTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEzPiCwTR?= NIXMbo9USU6JRWK=
ABC-1 cell Ml7FS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXPJcohq[mm2aX;uJI9nKGi3bXHuJGFDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlUhdk1? MYXTRW5ITVJ?
A2780 cell MlTmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1TDXmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU6PCCwTR?= NEPVcFFUSU6JRWK=
ES1 cell NWflOHhUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1L4VmlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63OFkhdk1? M2DqSnNCVkeHUh?=
HUTU-80 cell M1ji[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYHJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc6OSCwTR?= M2rEZ3NCVkeHUh?=
NCI-H292 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QDZibl2= NF3FWYJUSU6JRWK=
NB69 cell MlfoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYCxdlFbUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOiCwTR?= MlXIV2FPT0WU
ES8 cell NFXtN3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwM{Kgcm0> MVvTRW5ITVJ?
BCPAP cell NWjJVWdqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXLlXnNVUW6qaXLpeIlwdiCxZjDoeY1idiCEQ2DBVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzRibl2= MoG3V2FPT0WU
T-24 cell MlTrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1nK[WlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVUhdk1? NY\sb3NtW0GQR1XS
EW-16 cell NU\yV41{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MljjTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlEhdk1? NVnBfpRJW0GQR1XS
OVCAR-5 cell M1HPcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFvjVJJKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjh|IH7N NEfZS2FUSU6JRWK=
SF126 cell M{\zVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1jyVGlvcGmkaYTpc44hd2ZiaIXtZY4hW0ZzMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk2KG6P MYrTRW5ITVJ?
KP-4 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2Tz[2lvcGmkaYTpc44hd2ZiaIXtZY4hU1BvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVchdk1? MYHTRW5ITVJ?
GAMG cell NVjxSHc3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NInJWW9KdmirYnn0bY9vKG:oIHj1cYFvKEeDTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlUyKG6P MWHTRW5ITVJ?
HOS cell NFPoTpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHlTY5pcWKrdHnvckBw\iCqdX3hckBJV1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWzJI5O NIrjenZUSU6JRWK=
CHL-1 cell NV\DWGtZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{\4V2lvcGmkaYTpc44hd2ZiaIXtZY4hS0iOLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlgyKG6P NEHu[2dUSU6JRWK=
AGS cell NW\sdJFuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYHJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOE[gcm0> NWPDWWw6W0GQR1XS
MDA-MB-157 cell MoDYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1;PcmlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVE2PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUKgcm0> Mm\hV2FPT0WU
HSC-3 cell M2nDS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1XDd2lvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlAzKG6P NVu0NYlRW0GQR1XS
CAL-72 cell NYi2RYJ2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1i3WGlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?= MYfTRW5ITVJ?
NBsusSR cell MkjJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHrKRWVKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjF|IH7N NV7wSHlnW0GQR1XS
ES7 cell Mly3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGVUPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNUmgcm0> M1qwbnNCVkeHUh?=
H-EMC-SS cell NVywTmdJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoHnTY5pcWKrdHnvckBw\iCqdX3hckBJNUWPQz3TV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjhibl2= MlLXV2FPT0WU
NCI-H1703 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH\y[ldKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVcxOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNkigcm0> NYPv[5BCW0GQR1XS
BHT-101 cell Mnq3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUXxNYMzUW6qaXLpeIlwdiCxZjDoeY1idiCESGStNVAyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55MjDuUS=> NWXBO5ZRW0GQR1XS
SK-OV-3 cell M4H1TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXT2U5RjUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55NTDuUS=> NVvjcI8xW0GQR1XS
EW-24 cell MnnwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4XRXWlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlg{KG6P MVLTRW5ITVJ?
PSN1 cell M4PWdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJHBUVjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lki0JI5O NITPcWpUSU6JRWK=
OVCAR-8 cell MkjBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHLwSG1KdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njl7IH7N MYfTRW5ITVJ?
NCI-H1563 cell NGHXSpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{e4NmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVY{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5zMzDuUS=> M2ezPXNCVkeHUh?=
SW756 cell NUDYXWN[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xN{BvVQ>? NUmz[XBDW0GQR1XS
A375 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEXxT3VKdmirYnn0bY9vKG:oIHj1cYFvKEF|N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE1KG6P MmiwV2FPT0WU
Ca9-22 cell M2\OR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVLGV|RuUW6qaXLpeIlwdiCxZjDoeY1idiCFYUmtNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjJ3IH7N NI[xOopUSU6JRWK=
SW1990 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHNYOTl7MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuN|Ihdk1? NHzGVI5USU6JRWK=
ES4 cell M3T3dGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoLkTY5pcWKrdHnvckBw\iCqdX3hckBGWzRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkO5JI5O NVrhSJdQW0GQR1XS
HCE-T cell M36wVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXzJcohq[mm2aX;uJI9nKGi3bXHuJGhETS2WIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60OUBvVQ>? MontV2FPT0WU
MOLT-16 cell MlfDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4SycWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPTNibl2= MXHTRW5ITVJ?
HSC-4 cell NHjZ[WVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHfHW2hKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE45KG6P M4DLZnNCVkeHUh?=
NCI-SNU-1 cell NVfLWY9WT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF3TSGpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwOE[gcm0> M2fONnNCVkeHUh?=
EW-11 cell Moe1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND65JI5O NGe1SJhUSU6JRWK=
HT-1080 cell M3\lbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYTJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTFyOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlk6KG6P M{X5PXNCVkeHUh?=
MES-SA/Dx5 cells NF\WW3lEgXSxdH;4bYNqfHliYYPzZZk> MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXMuW0FxRIi1JINmdGy|LDDJR|UxRTVibl2= NGLKTlYzOzl|N{m4NS=>
SW1710 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mnu1TY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlE3KG6P M3\keXNCVkeHUh?=
EW-1 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlTpTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6yOEBvVQ>? Mne3V2FPT0WU
BV-173 cell M1z5OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYHJcohq[mm2aX;uJI9nKGi3bXHuJGJXNTF5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuN|khdk1? M{TkVHNCVkeHUh?=
TE-8 cell NVPGNWE1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFvkbnpKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQyKG6P NHr4WHlUSU6JRWK=
G-401 cell M3XLXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60N{BvVQ>? M2DzU3NCVkeHUh?=
KOSC-2 cell MkjwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIHERVdKdmirYnn0bY9vKG:oIHj1cYFvKEuRU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDVibl2= MnTaV2FPT0WU
HuCCT1 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{nQbWlvcGmkaYTpc44hd2ZiaIXtZY4hUHWFQ2SxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42OiCwTR?= NHLpO4pUSU6JRWK=
FADU cell NUnQ[XpNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEfvUWpKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY3KG6P MXzTRW5ITVJ?
MHH-ES-1 cell M4Gwcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJG1JUC2HUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43QSCwTR?= MX\TRW5ITVJ?
ES3 cell Mn;TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkPpTY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lke5JI5O M2XR[nNCVkeHUh?=
OVCAR-4 cell MoTSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVy4R45HUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=> M1Pj[HNCVkeHUh?=
HD-MY-Z cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{XOXmlvcGmkaYTpc44hd2ZiaIXtZY4hUERvTWmtXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTFibl2= MmPkV2FPT0WU
human JAR cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEHQeYlKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVchdk1? NV76VIU3W0GQR1XS
A427 cell MlPrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXLJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkC3JI5O Mo\UV2FPT0WU
697 cell NVW5WJc3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2Xk[2lvcGmkaYTpc44hd2ZiaIXtZY4hPjl5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6xN{BvVQ>? NFXoeGFUSU6JRWK=
OVCAR-3 cell MlnWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV\J[Wg5UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5{IH7N MVHTRW5ITVJ?
human NB14 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkHpTY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj62OEBvVQ>? MkDhV2FPT0WU
GB-1 cell M{fKSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3ja[mlvcGmkaYTpc44hd2ZiaIXtZY4hT0JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uO|Ehdk1? NXrZe|RbW0GQR1XS
COR-L105 cell M{DTT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{\zcmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyxNFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03Njd4IH7N NEiwZ5JUSU6JRWK=
647-V cell NX3XTIV5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIfmXoFKdmirYnn0bY9vKG:oIHj1cYFvKDZ2Nz3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok46KG6P MXvTRW5ITVJ?
human K5 cell NFGzWGVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn\hTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdibl2= NI\VOlBUSU6JRWK=
DMS-273 cell NGHYNIlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MojtTY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?= NFTMVnZUSU6JRWK=
UM-UC-3 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnTCTY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?= NYnn[odJW0GQR1XS
HEL cell Mn3jS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2XmWWlvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz6wPEBvVQ>? NWn2V2oyW0GQR1XS
human KU-19-19 cell M2HhW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmDZTY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODlibl2= NEfaRmhUSU6JRWK=
MC-IXC cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3;zPGlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4yPyCwTR?= NEjwfm5USU6JRWK=
human H4 cell NILrVFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUDJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5{NTDuUS=> NUHlNoI{W0GQR1XS
NUGC-3 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{e2WWlvcGmkaYTpc44hd2ZiaIXtZY4hVlWJQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{OyCwTR?= NIniW4FUSU6JRWK=
CHP-212 cell NF;iPYxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1X4O2lvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzRibl2= MXPTRW5ITVJ?
human SW982 cell M4Lrdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFf0SpZKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?= MnLDV2FPT0WU
C-33-A cell M2[xfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3vNcGlvcGmkaYTpc44hd2ZiaIXtZY4hSy1|Mz3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{42QCCwTR?= NGLFbmVUSU6JRWK=
PC-3 cell M2XjSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYHS[lB7UW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45QSCwTR?= NU[2O3ZzW0GQR1XS
COLO-684 cell NVO1VYNlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXjJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU4zOSCwTR?= MonNV2FPT0WU
SNU-387 cell M3;VUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVjJcohq[mm2aX;uJI9nKGi3bXHuJHNPXS1|OEegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25MlQ6KG6P NFnRS|JUSU6JRWK=
U251 cell NYHYem9vT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4C1WWlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuPFYhdk1? MnTWV2FPT0WU
A673 cell MmewS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHHFXXFKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU43KG6P NGe0cZVUSU6JRWK=
human T47D cell NX24enNGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVzJcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNj63PUBvVQ>? MmDmV2FPT0WU
A549 cell MlK5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mo\xTY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUmuOkBvVQ>? MY\TRW5ITVJ?
PC-14 cell NFzadnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoTUTY5pcWKrdHnvckBw\iCqdX3hckBRSy1zNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK0Mlc{KG6P NX;rRo9WW0GQR1XS
A704 cell Ml;vS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEX2TJlKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yO{41PSCwTR?= MUfTRW5ITVJ?
MCF7 cell NVnHS|JMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXfXS|NxUW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|EvOzZibl2= M{XrS3NCVkeHUh?=
PC3 cells NUDIVGJDTnWwY4Tpc44h[XO|YYm= MW\Jcohq[mm2aX;uJI9nKFCGS{GtcYVlcWG2ZXSgRWtVKHCqb4PwbI9zgWyjdHnvckBifCCWaIKzNFghemW|aXT1[UBqdiCqdX3hckBRSzNiY3XscJMh[nliRVzJV2EtKEmFNUC9NE4yOTNizszN NU[yZ3ZnOjF|NEG2O|U>
F-36P cells NHnpcIxRem:uaX\ldoF1cW:wIHHzd4F6 M133fmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRj2zOnAh[2WubIOsJGlEPTB;MD6yPEDPxE1? M33oR|IyOzRzNke1
OCI-AML2 cells NEDGbmZRem:uaX\ldoF1cW:wIHHzd4F6 M1\iNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT1PJMWFOVDJiY3XscJMtKEmFNUC9NE4{PSEQvF2= NVPwfZRuOjF|NEG2O|U>
K562 cells MkHwVJJwdGmoZYLheIlwdiCjc4PhfS=> NU\KZ2o6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUG4JO69VQ>? Mm\LNlE{PDF4N{W=

... Click to View More Cell Line Experimental Data

In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2

CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT01280786 Unknown status Acute Myeloid Leukemia Synta Pharmaceuticals Corp. January 2011 Phase 1
NCT00888615 Active not recruiting Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Tumor|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 13 2010 Phase 2
NCT00888615 Active not recruiting Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Mucinous Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Brenner Tumor|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Tumor|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma Gynecologic Oncology Group|National Cancer Institute (NCI) December 13 2010 Phase 2
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1
NCT00827203 Suspended Metastatic Solid Tumors Synta Pharmaceuticals Corp. January 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we use the compound for in vivo mouse studies?

  • Answer:

    S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products0

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID